U070 Immunostaining in Mohs Surgery: Impact, Interpretation, and Implementation
DESCRIPTION
Open admission to eligible categories, no tuition or ticket
Immunohistochemistry (IHC) in Mohs micrographic surgery offers key advantages in interpreting frozen section histology particularly in the treatment of melanoma, squamous cell carcinoma, and extramammary Paget’s disease. Recent advances in staining quality and specificity have led to increased adoption of IHC. This session will review the most commonly used immunostains, present clinical cases to outline immunostaining patterns during slide interpretation, delineate protocols and commercially available antibodies to facilitate implementation and quality improvement, and discuss the cost-effectiveness of IHC in the Mohs laboratory. This session will empower Mohs surgeons in any practice setting to integrate IHC into their surgical practice.
LEARNING OBJECTIVES
Demonstrate the role and impact of immunostaining in Mohs micrographic surgery
Discuss the framework for interpretation of immunostaining on frozen sections
Outline the steps to implementing immunohistochemistry in a Mohs surgery laboratory
SCHEDULE
12:00 PM
Introduction and impact of immunohistochemistry in Mohs surgery
Daniel Lewis, MD, FAAD
12:12 PM
Interpretation of MART-1 immunostaining in Mohs surgery for melanoma
Christine Ahn, MD, FAAD
12:24 PM
Interpretation of immunostains other than MART-1
Mary Elizabeth Lohman, MD, FAAD
12:36 PM
Implementation and cost-effectiveness of immunohistochemistry in the Mohs laboratory
Geoffrey Fung-Soon Lim, MD, FAAD
SPEAKERS
Christine Ahn, MD, FAAD
Daniel Lewis, MD, FAAD
Geoffrey Fung-Soon Lim, MD, FAAD
Mary Elizabeth Lohman, MD, FAAD
SPEAKER DISCLOSURES
Christine Ahn, MD, FAAD
No financial relationships exist with ineligible companies.
Daniel Lewis, MD, FAAD
No financial relationships exist with ineligible companies.
Geoffrey Fung-Soon Lim, MD, FAAD
No financial relationships exist with ineligible companies.
Mary Elizabeth Lohman, MD, FAAD
No financial relationships exist with ineligible companies.